Advances in peritoneal dialysis

Minerva Urologica e Nefrologica

Volumn 59, Issue 3, 2007, Pages 251-260

  Krediet, R T ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Biocompatible materials; Icodextrin; Peptide transport system; Peritoneal dialysis; Survival

Indexed keywords

4 AMINOHIPPURIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA 2 MICROGLOBULIN; CALCIUM CHANNEL BLOCKING AGENT; CARBOXYLIC ACID; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ICODEXTRIN; INSULIN; INTERLEUKIN 6; PLACEBO; RAMIPRIL; TRANSFORMING GROWTH FACTOR BETA; UREA;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG MECHANISM; DRUG MEGADOSE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; INTERMETHOD COMPARISON; KIDNEY FUNCTION; LONG TERM CARE; MORTALITY; PATIENT TRANSPORT; PERITONEAL DIALYSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL; TREATMENT DURATION; TREATMENT FAILURE; ULTRAFILTRATION; UREMIA;

HEMODIALYSIS SOLUTIONS; HUMANS; KIDNEY FUNCTION TESTS; PERITONEAL DIALYSIS;

EID: 36749085166     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Jager KJ, Korevaar JC, Dekker FW, Krediet RT, Boeschoten EW; The Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) study group. The effect of contraindications and patient preference on dialysis modality selection in ESRD patients in The Netherlands. Am J Kidney Dis 2004;43:891-9.
2. Collins AJ, Hao W, Xia H, Ebben JP, Everson SE, Constantini EG et al. Mortality risks of peritoneal dialysis and hemodialysis. Am J Kidney Dis 1999;34:1065-74.
3. Van Biesen W, Vanholder RC, Veys N, Dhondt A, Lameire N. An evaluaton of an integrative care approach for end-stage renal disease patients. J Am Soc Nephrol 2000;11:116-25.
4. Jager KJ, Merkus MP, Boeschoten EW, Dekker FW, Tijssen JCP, Krediet RT; The NECOSAD study group. What happens to patients starting dialysis in The Netherlands? Neth J Med 2001;58:163-73.
5. Locatelli F, Marcello D, Conte F, D'Amico M, Del Vecchio L, Limido A et al. Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease. Am J Soc Nephrol 2001;12:2411-7.
6. Termorshuizen F, Koreveaar JC, Dekker FW, van Manen JG, Boeschoten EW, Krediet RT et al. Hemodialysis and peritoneal dialysis: comparison of adjusted mortality rates according to the duration of dialysis. Analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis 2. J Am Soc Nephrol 2003;14:2851-60.
7. Collins AJ, Hao W, Xia H, Ebben JP, Everson SE, Constantini EG et al. Mortality risks of peritoneal dialysis and hemodialysis. Am J Kidney Dis 1999;34:1065-74.
8. Davies SJ, van Biesen W, Nicholas J, Lameire N. Integrated care. Perit Dial Int 2001;21(Suppl 3):S 269-74.
9. Heaf JG, Løkkegaard H, Madson M. Initial survival advantage of peritoneal dialysis relative to haemodialysis. Nephrol Dial Transplant 2002;17:112-7.
10. Vonesh EF, Snyder JJ, Foley RN, Collins AJ. The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. Kidney Int 2004;66:2389-2401.
11. Liem YS, Wong JB, Hunnik MGM, De Charro FTh, Winkelmayer WC. Comparison of hemodialysis and peritoneal dialysis survival in The Netherlands. Kidney Int 2007;72:153-8.
12. Jaar BG, Coresh J, Plantinga LC, Fink NE, Klag MJ, Levey AS et al. Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann Intern Med 2005;143:174-83.
13. Korevaar JC, Feith GW, Dekker FW, van Manen JG, Boeschoten EW, Bossuyt PMM et al. Effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: a randomized controlled trial. Kidney Int 2003;64:2222-8.
14. Fenton SSA, Schaubel DE, Desmeules M, Morrison HI, Mao Y, Copleston P et al. Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates. Am J Kidney Dis 1997;30:334-42.
15. NKF-DOQ1 clinical practice guidelines for peritoneal dialysis adequacy. National Kidney Foundation. Am J Kidney Dis 1997;30:S67-S136.
16. Schoots A, Vanholder R, Gladdines M, de Smet R, Cramers C, Ringoir S. Hippuric acid and an unidentified compound as possible indicators of residual renal function in dialyzed patients. In: Smeby, Jorstad, Wideroë, editors. Immune and metabolic aspects of therapeutic blood purification systems. Basel: Karger; 1986.p.240-5.
17. Van Olden RW, van Acker BA, Koomen GC, Krediet RT, Arisz L. Contribution of tubular anion and cation secretion to residual renal function in chronic dialysis patients. Clin Nephrol 1998;49:167-72.
18. Amici G, Virga G, Da Rin G, Grandesso S, Vianello A, Gatti P et al. Serum beta-2-microglobulin level and residual renal function in peritoneal dialysis. Nephron 1993;65:469-71.
19. McCarthy JT, Williams AW, Johnson WJ. Serum beta-2-microglobulin concentration in dialysis patients: importance of intrinsic renal function. J Lab Clin Med 1994;123:495-505.
20. urea-nPNA in anuric PD patients, a comparison with predialysis patients. Perit Dial Int 2001;21:509-15.
21. Wang AYM, Sea MMM, Ip R, Law MC, Chow KM, Lui SF et al. Independent effects of residual renal function and dialysis adequacy on actual dietary protein, calorie, and other nutrient intake in patients on continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 2001;12:2450-7.
22. Bargman JM, Thorpe KE, Churchill DN for the CANUSA peritoneal dialysis study group. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001;12:2158-62.
23. Termorshuizen F, Korevaar JC, Dekker FW, van Manen JG, Boeschoten EW, Krediet RT;the NECOSAD study group. The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on Adequacy of Dialysis (NECOSAD)-2. Am J Kidney Dis 2003;41:1293-302.
24. Termorshuizen F, Dekker FW, van Manen JG, Korevaar JC, Boeschoten EW, Krediet RT; the NECOSAD study group. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 2004;15:1061-70.
25. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J et al.; Mexican nephrology collahorative study group. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized controlled trial. J Am Soc Nephrol 2002;13:1307-20.
26. Lo WK, Ho YW, Li CS, Wong KS, Chan TM, Yu A WF et al. Effects of Kt/V on survival and clinical outcome in CAPD patients in a randomized prospective study. Kidney Int 2003;64:649-56.
27. McKane W, Chandna SM, Tattersall JE, Greenwood RN, Farrington K. Identical decline of residual renal function in high-flux biocompatible hemodialysis and CAPD. Kidney Int 2002;61:256-65.
28. Moist LM, Port FK, Orzol SM, Young EW, Ostbye T, Wolfe RA et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000;11:556-64.
29. Jansen MAM, Hart AAM, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT; the NECOSAD study group. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int 2002; 62: 1046-53.
30. Rottembourg J, Issad B, Gallego JL, Degoulet P, Aime F, Gueffaf B et al. Evolution of residual renal function in patients undergoing maintenance haemodialysis or continuous ambulatory peritoneal dialysis. Proc Eur Dial Transplant Assoc 1983;19:397-403.
31. Cancarini GC, Brunori G, Camerini C, et al. Renal function recovery and maintenance of residual diuresis in CAPD and hemodialysis. Perit Dial Bull 1986;6:77-9.
32. Lysaght MJ, Vonesh EF, Gotch F, Ibels L, Keen M, Lindholm B et al. The influence of dialysis treatment modality on the decline of remaining renal function. ASAIO Trans 1991;37:598-604.
33. Misra M, Vonesh E, van Stone JC, Moore HL, Prowant B, Nolph KD. Effect of cause and time of dropout on the residual GFR: a comparative analysis of the decline of GFR on dialysis. Kidney Int 2002;59:754-63.
34. Lang SM, Bergner A, Topfer M, Schiffl H. Preservation of residual renal function in dialysis patients: effect of dialysis-technique related factors. Perit Dial Int 2001;21:52-7.
35. Van Olden RW, Guchelaar H-J, Struijk DG, Krediet RT, Arisz L. Acute effects of high-dose furosemide on residual renal function in CAPD patients. Perit Dial Int 2003;23:339-47.
36. Medcalf JF, Harris KPG, Walls J. Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int 2001;59:1128-33.
37. Li PKT, Chow KM, Wong TYH, Leung CB, Szeto CC. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. Ann Intern Med 2003;139:105-12.
38. Twardowski ZJ, Nolph KD, Khanna R, Prowant B, Ryan LP, Moore HL et al. Peritoneal equilibration test. Perit Dial Bull 1987;7:138-47.
39. Wang T, Heimbürger O, Waniewski J, Bergström J, Lindholm B. Increased peritoneal permeability is associated with decreased small-solute removal and higher mortality in CAPD patients. Nephrol Dial Transplant 1998;13:1242-9.
40. Churchill DN, Thorpe KE, Nolph KD, Keshaviah PR, Oreopoulos DG, Pagé D; the CANUSA study group. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. J Am Soc Nephrol 1998;9:1285-92.
41. Brimble KS, Walker M, Margetts PJ, Kundhal KK, Rabbat CG. Meta-analysis: peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis. J Am Soc Nephrol 2006;17:2591-8.
42. Rumpsfeld M, McDonald SP, Johnson DW. Higher peritoneal transport status is associated with higher mortality and technique failure in the Australian and New Zealand peritoneal dialysis patient populations. J Am Soc Nephrol 2006;17:271-8.
43. Ates K, Nergizoglu G, Keven K, Sen A, Kutlay S, Erturk S et al. Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney Int 2001;60:767-76.
44. Chung SH, Chu WS, Lee HA, Kim YH, Lee IS, Lindholm B et al. Peritoneal transport characteristics, comorbid diseases and survival in CAPD patients. Perit Dial Int 2000;20:541-7.
45. Rumpsfeld M, McDonald SP, Purdie DM, Collins J, Johnson DW. Predictors of baseline peritoneal transport status in Australian and New Zealand peritoneal dialysis patients. Am J Kidney Dis 2004;43:492-501.
46. Topley N, Williams JD. Role of the peritoneal membrane in the control of inflammation in the peritoneal cavity. Kidney Int 1994;46(Suppl 48):S71-S78.
47. Selgas R, del Peso G, Bajo MA, Castro ML, Molina S, Cirugeda A et al. Spontaneous VEGF production by cultured mesothelial cells from patients on peritoneal dialysis. Perit Dial Int 2000;20:798-801.
48. Visser CE, Brouwer-Steenbergen JJE, Betjes MGH, Koomen GCM, Beelen RHJ, Krediet RT. Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients. Nephrol Dial Transplant 1995;10:64-9.
49. Topley N, Jörres A, Luttmann W, Petersen M, Lang M, Thierausch KH et al. Human peritoneal mesothelial cells synthesize IL-6: induction by IL-Iβ and TNFα. Kidney Int 1993;43:226-33.
50. Betjes MGH, Tuk CW, Struijk DG, Krediet RT, Arisz L, Hart M et al. Interleukin-8 production by human peritoneal mesothelial cells in response to tumor necrosis factor-α, interleukin-1 and medium conditions by macrophages co-cultured with Staphylococcus epidermidis. J Infect Dis 1993;168:1202-10.
51. Ho-Dac-Pannekeet MM, Krediet RT. Inflammatory changes in vivo during CAPD. What can the effluent tell us? Kidney Int 1996;50(Suppl 56):S12-S16.
52. Krediet RT. Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis. Perit Dial Int 2001;21:560-7.
53. Davies SJ, Brian J, Phillips L, Russel GI. The predictive value of Kt/V and peritoneal solute transport in CAPD patients in dependent on the type of comorbidity present. Perit Dial Int 1990;16(Suppl 1):S158-S162.
54. Pecoits-Filho R, Araujo MRT, Lindholm B, Stenvinkel P, Abensur H, Romão JE et al. Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. Nephrol Dial Transplant 2002;17:1480-6.
55. Pecoits-Filho R, Carvalho MJ, Stenvinkel P, Lindholm B, Heimburger O. Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Perit Dial Int 2006;26:53-63.
56. Rodrigues A, Martins M, Santos MJ, Fonseca I, Oliveira JC, Cabrita A et al. Evaluation of effluent markers cancer antigen 125, vascular endothelial growth factor and interleukin-6: Relationship with peritoneal transport. Adv Perit Dial 2004;20:8-12.
57. Rodrigues AS, Martins M, Korevaar JC, Silva S, Oliveira JC, Cabrita A et al. Evaluation of peritoneal transport and membrane status in peritoneal dialysis: focus on incident fast transporters. Am J Nephrol 2007;27:84-91.
58. Van Esch S, Zweers MM, Jansen MAM, de Waart DR, van Manen JG, Krediet RT. Determinants of peritoneal solute transport rates in newly started nondiabetic peritoneal dialysis patients. Perit Dial Int 2004;24:554-61.
59. Krediet RT, Zuyderhoudt FMJ, Boeschoten EW, Arisz L. Alterations in the peritoneal transport of water and solutes during peritonitis in continuous ambulatory peritoneal dialysis patients. Eur J Clin Invest 1987;17:43-52.
60. Douma CE, de Waart DR, Struijk DG, Krediet RT. Are phospholipase A2 and nitric oxide involved in the alterations in peritoneal transport during CAPD peritonitis? J Lab Clin Med 1998;132:329-40.
61. Smit W, van den Berg N, Schouten N, Aikens E, Struijk DG, Krediet RT. Free water transport in fast transport status: a comparison between CAPD peritonitis and long-term PD. Kidney Int 2004;65:298-303.
62. Zemel D, Koomen GCM, Hart AAM, ten Berge RJM, Struijk DG, Krediet RT. Relationship of TNF-α, interleukin-6 and prostogladins to peritoneal permeability for macromolecules during longitudinal follow-up of peritonitis in continuous ambulatory peritoneal dialysis. J Lab Clin Med 1993;122:686-96.
63. Heimburger O, Waniewski J, Werynski A, Traneaus A, Lindholm B. Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int 1990;38:495-506.
64. Smit W, Schouten N, van den Berg N, Langedijk M, Struijk DG, Krediet RT; the Netherlands Ultrafiltration failure study group. Analysis of the prevalence and causes of ultrafiltration failure during long-term peritoneal dialysis: a cross sectional study. Perit Dial Int 2004;24:562-70.
65. Krediet RT, Lindholm B, Rippe B. Pathophysiology of peritoneal membrane failure. Perit Dial Int 2000;20(Suppl 4):S22-S42.
66. Numata M, Nakayama M, Nimura S, Kawakami M, Lindholm B, Kawaguchi Y. Association between an increased surface area of peritoneal microvessels and a high peritoneal solute transport rate. Perit Dial Int 2003;23:116-22.
67. Honda K, Nitta K, Horita S, Yumura W, Nikei H. Morphological changes in the vasculature of patients on CAPD with ultrafiltration failure. Nephron 1996;72:171-6.
68. Mateijsen MAM, van der Wal AC, Hendriks PMEM, Zweers MM, Mulder JB, Struijk DG et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999;19:517-25.
69. Williams JD, Craig KJ, Topley N, von Ruhland C, Fallon M, Newman GR et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002;13:470-9.
70. Davies SJ. Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney Int 2004;66:2437-45.
71. Smit W, Struijk DG, Ho-dac-Pannekeet MM, Krediet RT. Quantification of free water transport in peritoneal dialysis. Kidney Int 2004;66:849-54.
72. Parikova A, Smit W, Struijk DG, Krediet RT. Analysis of fluid transport pathways and their determinants in peritoneal dialysis patients with ultrafiltration failure. Kidney Int 2006;70:1988-94.
73. Brown EA, Davies SJ, Rutherford P, Meeus F, Borras M, Riegel W et al. Survival of functionally anuric patients on automated peritoneal dialysis: the European APD Outcome Study. J Am Soc Nephrol 2003;14:2948-57.
74. Jansen MAM, Termorshuizen F, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT; the NECOSAD study group. Predictors of survival in anuric peritoneal dialysis patients. Kidney Int 2005;68:1199-205.
75. Dobbie JW. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992;12:14-27.
76. Di Paolo N, Sacchi G, De Mia M, Gaggiotti E, Capotondo L, Rossi P et al. Morphology of the peritoneal membrane during continuous ambulatory peritoneal dialysis. Nephron 1986;44:204-11.
77. Yanez-Mo M, Lara-Pezzi E, Selgas R, Ramirez-Huesca M, Dominguez-Jimenez C, Jimenez-Hefferman JA et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 2007;348:403-13.
78. Di Paolo N, Sacchi G. Peritoneal vascular changes in continuous ambulatory peritoneal dialysis (CAPD): an in vivo model for the study of diabetic microangiopathy. Perit Dial Int 1989;9:41-5.
79. Davies SJ, Bryan J, Phillips L, Russel GI. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 1996;11: 498-506.
80. Davies SJ, Phillips L, Naish PF, Russel GI. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 2001;12:1046-51.
81. Mistry CD, Gokal R. Can ultrafiltration occur with a hypo-osmolar solution in peritoneal dialysis? The role for "colloid" osmosis. Clin Sci 1993;85:495-500.
82. Ho-dac-Pannekeet MM, Schouten N, Langedijk MJ, Hiralall JK, De Waart DR, Struijk DG et al. Peritoneal transport characteristics with glucose polymer based dialysate. Kidney Int 1996;50:979-86.
83. Finkelstein F, Healy H, Abu-Alfa A, Ahmad S, Brown F, Gehr T, et al.; the icodextrin high transporter trial group. Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol 2005;16:546-54.
84. Davies SJ, Woodrow G, Donovan K, Plum J, Williams P, Johansson C et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol 2003;14:2338-44.
85. Konings CCJAM, Kooman JP, Schonk M, Gladriwa U, Wirtz J, van den Wall Bake W et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney Int 2003;63:1556-63.
86. Hoff CM. In vitro biocompatibility performance of Physioneal. Kidney Int 2003;64:(Suppl 88):S57-S74.
87. Skoufos L, Topley N, Cooker L, Dawnay A, Millar DJ, Holmes CJ et al. The in vitro biocompatibility performance of a 25 mmol/L bicarbonate 10 mmol/L lactate-buffered peritoneal dialysis fluid. Kidney Int 2003; 64(Suppl 88):S94-S99.
88. Mortier S, DeVriese AS, Van de Voorde J, Schaub TP, Passlick-Deetjen J, Lameire N. Hemodynamic effect of peritoneal dialysis solutions on the rat peritoneal membrane: role of acidity, buffer choice, glucose concentration and glucose degradation products. J Am Soc Nephrol 2002:13:480-9.
89. Hekking LH, Zareie M, Driesprong BA, Faict D, Welten AGA, de Greeuw I et al. Better preservation of peritoneal morphologic features and defense in rats after longterm exposure to a bicarbonate lactate-buffered solution. J Am Soc Nephrol 2001;12:2775-86.
90. Ter Wee PM, Beelen RHJ, van den Born J. The application of animal models to study the biocompatibility of bicarbonate-buffered peritoneal dialysis solutions. Kidney Int 2003;64(Suppl 88):S75-83.
91. Mckenzie RK, Holmes CJ, Moseley A, Jenkins JP, Williams JD, Coles GA et al. Bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improve ex vivo peritoneal TNF alpha secretion. J Am Soc Nephrol 1998;9:1499-1506.
92. Do JY, Kim YL, Park JW, Cho KH, Kim TW, Yoon KW et al. The effect of low glucose degradation product dialysis solution on epithelial-to- mesenchymal transition in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 2005;25(Suppl 3):S22-5.
93. Rippe B, Simonsen O, Heimburger O, Christensson A, Haraldsson B, Stelin G et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001;59:348-57.
94. Jones S, Holmes CJ, Krediet RT, Mackenzie R, Faict D, Tranaeus A et al. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreces hyaluronic acid levels. Kidney Int 2001:59:1529-38.
95. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Cage C et al. The Eurobalance trial: the effect of a new biocompatible peritoneal dialysis fluid (Balance) on the peritoneal membrane. Kidney Int 2004;66:408-18.
96. Haas S, Schmitt CP, Arbeiter K, Bonzel KE, Fischbach M, John U et al. J Am Soc Nephrol 2003;14:2632-8.
97. Mactier RA, Sprosen TS, Gokal R, Williams PF, Lindbergh M, Naik RB et al. Bicarbonate and bicarbonate/lactate PD solutions for the treatment of infusion pain. Kidney Int 1998;53:1061-7.
98. Parikova A, Struijk DG, Zweers MM, Langedijk M, Schouten N, van den Berg N et al. Does the biocompatibility of the PD solution matter for the assessment of peritoneal function? Perit Dial Int 2007;27. In press.
99. Zeier M, Schwenger V, Deppisch R, Hang U, Weigel K, Bahner U et al. Glucose degradation products in PD fluids: do they disappear form the peritoneal cavity and enter the systemic circulation? Kidney Int 2003;63:298-305.
100. Lee HY, Park HC, Seo BJ, Bo SY, Yun SR, Song HY et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance)'. Perit Dial Int 2005;25:248-55.